Who founded Bioeclipse?

Bioeclipse was founded by Pamela Reilly Contag.

Who are Bioeclipse's investors?

Bioeclipse's investors include Foothill Ventures, Plum Alley Investments.

How much funding has Bioeclipse raised?

Bioeclipse has disclosed $10.1M raised across 1 round.

Where is Bioeclipse headquartered?

Bioeclipse is headquartered in South San Francisco, US.

Bioeclipse

South San Francisco, US · Delaware corporation · 2 known investors

BioEclipse Therapeutics is a clinical-stage oncology company developing immuno-oncology therapeutics using a proprietary platform that targets the tumor microenvironment through engineered immune cell therapies. The company's approach combines multiple mechanisms of action to eradicate cancer cells and generate durable immune responses against relapse and recurrence.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Pamela Reilly ContagFounder

Catherine SohnNamed on SEC filing

Gregory SchiffmanNamed on SEC filing

Mark FrohlichNamed on SEC filing

Stephen ThauNamed on SEC filing

Elona BaumNamed on SEC filing

Benjamin CarterNamed on SEC filing

Board

Biao HeBoard directorVenture Partner at Foothill Ventures

Investors · 2

Foothill VenturesLos Altos · $100K – $10M

Plum Alley InvestmentsNew York · $500K – $1.5M

Reported raises · per SEC filings

Form D private placements

$10.1M disclosed across 1 round · 2019

▶$10.1MraisedOct 2019 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Catherine SohnDirector
Gregory SchiffmanDirector
Biao HeDirector
Mark FrohlichDirector
Stephen ThauExecutive Officer
Elona BaumDirector
Pamela Reilly ContagExecutive Officer, Director
Benjamin CarterExecutive Officer

Offering amount: $11.8M
Amount sold: $10.1M
Finders' fees: $131.8K
Placement agents: Venture.co Brokerage Services LLC
First sale: Jun 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Solu4 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies competing with Bioeclipse for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Bioeclipse do?: BioEclipse Therapeutics is a clinical-stage oncology company developing immuno-oncology therapeutics using a proprietary platform that targets the tumor microenvironment through engineered immune cell therapies. The company's approach combines multiple mechanisms of action to eradicate cancer cells and generate durable immune responses against relapse and recurrence.
Who founded Bioeclipse?: Bioeclipse was founded by Pamela Reilly Contag.
Who are Bioeclipse's investors?: Bioeclipse's investors include Foothill Ventures, Plum Alley Investments.
How much funding has Bioeclipse raised?: Bioeclipse has disclosed $10.1M raised across 1 round.
Where is Bioeclipse headquartered?: Bioeclipse is headquartered in South San Francisco, US.